# Comparison of the Bioavailability of Fenofibric Acid and Rosuvastatin From 5/45 mg Strength of ABT-143 Relative to That From the Coadministration of ABT-335 (Fenofibric Acid) 45 mg and Rosuvastatin Calcium 5 mg

> **NCT00826358** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 90 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** ABT-143
- **DRUG:** ABT-335
- **DRUG:** rosuvastatin

## Key facts

- **NCT ID:** NCT00826358
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** 2008-11
- **Final completion:** —
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2012-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00826358

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00826358, "Comparison of the Bioavailability of Fenofibric Acid and Rosuvastatin From 5/45 mg Strength of ABT-143 Relative to That From the Coadministration of ABT-335 (Fenofibric Acid) 45 mg and Rosuvastatin Calcium 5 mg". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00826358. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*